Fig. 5From: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwana Mean DAS28-CRP changes from baseline, b patient proportions achieving DAS28-CRP score < 2.6 (FAS)Back to article page